You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEntacapone
Accession NumberDB00494  (APRD00416)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionEntacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration of levodopa and a decarboxylase inhibitor.
Structure
Thumb
Synonyms
(e)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
Comtan
Comtess
Entacapona
Entacapone
Entacaponum
N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide
External Identifiers
  • OR 611
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Auro-entacaponeTablet200 mgOralAuro Pharma IncNot applicableNot applicableCanada
ComtanTablet200 mgOralNovartis Pharmaceuticals Canada Inc2001-06-21Not applicableCanada
ComtanTablet, film coated200 mgOralNovartis Europharm Limited1998-09-22Not applicableEu
ComtanTablet, film coated200 mg/1OralNovartis Pharmaceuticals Corporation1999-10-19Not applicableUs
ComtanTablet, film coated200 mgOralNovartis Europharm Limited1998-09-22Not applicableEu
ComtanTablet, film coated200 mg/1OralCardinal Health2000-01-01Not applicableUs
ComtanTablet, film coated200 mgOralNovartis Europharm Limited1998-09-22Not applicableEu
ComtessTablet, film coated200 mgOralOrion Corporation1998-09-16Not applicableEu
ComtessTablet, film coated200 mgOralOrion Corporation1998-09-16Not applicableEu
ComtessTablet, film coated200 mgOralOrion Corporation1998-09-16Not applicableEu
ComtessTablet, film coated200 mgOralOrion Corporation1998-09-16Not applicableEu
EntacaponeTablet, film coated200 mg/1OralWockhardt Limited2012-09-30Not applicableUs
EntacaponeTablet, film coated200 mg/1OralKAISER FOUNDATION HOSPITALS2014-10-10Not applicableUs
EntacaponeTablet, film coated200 mg/1OralSun Pharma Global FZE2013-04-01Not applicableUs
EntacaponeTablet, film coated200 mg/1OralWockhardt Limited2012-09-30Not applicableUs
EntacaponeTablet, film coated200 mg/1OralMylan Pharmaceuticals Inc.2013-06-26Not applicableUs
EntacaponeTablet, film coated200 mg/1OralMylan Institutional Inc.2013-12-12Not applicableUs
EntacaponeTablet, film coated200 mg/1OralWockhardt USA LLC.2012-09-30Not applicableUs
EntacaponeTablet, film coated200 mg/1OralSandoz Inc2014-06-04Not applicableUs
EntacaponeTablet, film coated200 mg/1OralWockhardt USA LLC.2012-09-30Not applicableUs
EntacaponeTablet, film coated200 mg/1OralAvera Mc Kennan Hospital2015-09-23Not applicableUs
EntacaponeTablet, film coated200 mg/1OralAv Kare, Inc.2014-06-20Not applicableUs
EntacaponeTablet, film coated200 mg/1OralAphena Pharma Solutions Tennessee, Llc2012-09-30Not applicableUs
Entacapone OrionTablet, film coated200 mgOralOrion Corporation2011-08-18Not applicableEu
Entacapone OrionTablet, film coated200 mgOralOrion Corporation2011-08-18Not applicableEu
Entacapone OrionTablet, film coated200 mgOralOrion Corporation2011-08-18Not applicableEu
Entacapone OrionTablet, film coated200 mgOralOrion Corporation2011-08-18Not applicableEu
Mylan-entacaponeTablet200 mgOralMylan Pharmaceuticals Ulc2012-07-31Not applicableCanada
Sandoz EntacaponeTablet200 mgOralSandoz Canada Incorporated2012-03-30Not applicableCanada
Teva-entacaponeTablet200 mgOralTeva Canada Limited2012-03-29Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-entacaponeTablet200 mgOralApotex IncNot applicableNot applicableCanada
EntacaponeTablet, film coated200 mg/1OralSun Pharma Global FZE2012-07-18Not applicableUs
EntacaponeTablet, film coated200 mg/1OralAmerican Health Packaging2016-02-01Not applicableUs
EntacaponeTablet, film coated200 mg/1OralWockhardt Limited2012-08-16Not applicableUs
EntacaponeTablet, film coated200 mg/1OralAurobindo Pharma Limited2015-06-19Not applicableUs
EntacaponeTablet, film coated200 mg/1OralWockhardt USA LLC.2012-08-16Not applicableUs
Entacapone TevaTablet, film coated200 mgOralTeva Pharma B.V.2011-02-18Not applicableEu
Entacapone TevaTablet, film coated200 mgOralTeva Pharma B.V.2011-02-18Not applicableEu
Entacapone TevaTablet, film coated200 mgOralTeva Pharma B.V.2011-02-18Not applicableEu
Entacapone TevaTablet, film coated200 mgOralTeva Pharma B.V.2011-02-18Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnxoponeRoot
ComtadeNovartis
ComtessOrion
Brand mixtures
NameLabellerIngredients
Carbidopa, Levodopa and EntacaponeSun Pharma Global FZE
Carbidopa, Levodopa, and EntacaponeSandoz Inc
StalevoNovartis Pharmaceuticals Canada Inc
SaltsNot Available
Categories
UNII4975G9NM6T
CAS number130929-57-6
WeightAverage: 305.286
Monoisotopic: 305.101170605
Chemical FormulaC14H15N3O5
InChI KeyJRURYQJSLYLRLN-BJMVGYQFSA-N
InChI
InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+
IUPAC Name
(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
SMILES
CCN(CC)C(=O)C(=C\C1=CC(=C(O)C(O)=C1)[N+]([O-])=O)\C#N
Pharmacology
IndicationUsed as an adjunct to levodopa / carbidopa in the symptomatic treatment of patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-dose "wearing-off".
Structured Indications
PharmacodynamicsEntacapone is structurally and pharmacologically related to tolcapone, but unlike tolcapone, is not associated with hepatotoxicity. Entacapone is used in the treatment of Parkinson’s disease as an adjunct to levodopa/carbidopa therapy. Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT). In mammals, COMT is distributed throughout various organs with the highest activities in the liver and kidney. COMT also occurs in the heart, lung, smooth and skeletal muscles, intestinal tract, reproductive organs, various glands, adipose tissue, skin, blood cells and neuronal tissues, especially in glial cells. COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include dopa, catecholamines (dopamine, norepinephrine, and epinephrine) and their hydroxylated metabolites. The function of COMT is the elimination of biologically active catechols and some other hydroxylated metabolites. COMT is responsible for the elimination of biologically active catechols and some other hydroxylated metabolites. In the presence of a decarboxylase inhibitor, COMT becomes the major metabolizing enzyme for levodopa, catalyzing the it to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD) in the brain and periphery.
Mechanism of actionThe mechanism of action of entacapone is believed to be through its ability to inhibit COMT in peripheral tissues, altering the plasma pharmacokinetics of levodopa. When entacapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are greater and more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. It is believed that at a given frequency of levodopa administration, these more sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to a greater reduction in the manifestations of parkinsonian syndrome.
TargetKindPharmacological actionActionsOrganismUniProt ID
Catechol O-methyltransferaseProteinyes
inhibitor
HumanP21964 details
Related Articles
AbsorptionEntacapone is rapidly absorbed (approximately 1 hour). The absolute bioavailability following oral administration is 35%.
Volume of distribution
  • 20 L
Protein binding98% (bind to serum albumin)
Metabolism

Metabolized via isomerization to the cis-isomer, followed by direct glucuronidation of the parent and cis-isomer.

Route of eliminationEntacapone is almost completely metabolized prior to excretion, with only a very small amount (0.2% of dose) found unchanged in urine. As only about 10% of the entacapone dose is excreted in urine as parent compound and conjugated glucuronide, biliary excretion appears to be the major route of excretion of this drug.
Half life0.4-0.7 hour
Clearance
  • 850 mL/min
ToxicitySide effect include increase the occurrence of orthostatic hypotension, severe rhabdomyolysis, dyskinesia, hallucinations, hyperkinesia, hypokinesia, dizziness, fatigu,e gastrointestinal effects including abdominal pain constipation diarrhea nausea
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Entacapone is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Entacapone.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when Entacapone is combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Entacapone.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Entacapone.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Entacapone.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Entacapone.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Entacapone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Entacapone.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Entacapone.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Entacapone.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Entacapone.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Entacapone.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Entacapone.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Entacapone is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Entacapone.Experimental
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Entacapone.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Entacapone.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Entacapone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Entacapone.Vet Approved
AzelastineEntacapone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Entacapone is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Entacapone.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Entacapone.Illicit
BenmoxinThe risk or severity of adverse effects can be increased when Entacapone is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Entacapone is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Entacapone.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Entacapone.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Entacapone is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Entacapone.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Entacapone.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Entacapone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Entacapone.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Entacapone.Approved, Investigational
BuprenorphineEntacapone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Entacapone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Entacapone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Entacapone.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Entacapone.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Entacapone.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Entacapone.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Entacapone.Approved, Illicit, Vet Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Entacapone.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Entacapone is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Entacapone.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Entacapone.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Entacapone is combined with Caroxazone.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Entacapone.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Entacapone.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Entacapone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Entacapone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Entacapone.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Entacapone is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Entacapone.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Entacapone.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Entacapone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Entacapone.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Entacapone is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Entacapone.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Entacapone is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Entacapone.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Entacapone.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Entacapone is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Entacapone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Entacapone is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Entacapone.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Entacapone.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Entacapone.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Entacapone.Approved, Illicit
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Entacapone.Approved
CyclizineThe risk or severity of adverse effects can be increased when Entacapone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Entacapone.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Entacapone.Approved
DantroleneThe risk or severity of adverse effects can be increased when Entacapone is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Entacapone.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Entacapone is combined with Dapoxetine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Entacapone.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Entacapone.Approved
DesipramineThe risk or severity of adverse effects can be increased when Entacapone is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Entacapone is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Entacapone is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Entacapone.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Entacapone.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Entacapone.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Entacapone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Entacapone.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Entacapone.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Entacapone.Approved, Illicit, Vet Approved
DiethylstilbestrolThe metabolism of Diethylstilbestrol can be decreased when combined with Entacapone.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Entacapone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Entacapone.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Entacapone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Entacapone.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Entacapone is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Entacapone.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Entacapone.Approved, Illicit
DobutamineThe metabolism of Dobutamine can be decreased when combined with Entacapone.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Entacapone.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Entacapone.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Entacapone is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Entacapone.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Entacapone.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Entacapone is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Entacapone.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Entacapone.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Entacapone.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Entacapone is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Entacapone is combined with Efavirenz.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Entacapone.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Entacapone is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Entacapone.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Entacapone.Approved
EthanolEntacapone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Entacapone.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Entacapone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Entacapone is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Entacapone.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Entacapone.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Entacapone.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Entacapone.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Entacapone.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Entacapone.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Entacapone.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Entacapone is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Entacapone.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Entacapone is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Entacapone is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Entacapone.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Entacapone.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Entacapone is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Entacapone is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Entacapone.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Entacapone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Entacapone.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Entacapone is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Entacapone.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Entacapone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Entacapone.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Entacapone.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Entacapone is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Entacapone.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Entacapone is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Entacapone.Approved, Illicit
FurazolidoneThe risk or severity of adverse effects can be increased when Entacapone is combined with Furazolidone.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Entacapone.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Entacapone is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Entacapone.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Entacapone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Entacapone.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Entacapone is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Entacapone.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Entacapone.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Entacapone.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Entacapone.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Entacapone.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Entacapone is combined with Hydracarbazine.Approved
HydrocodoneEntacapone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Entacapone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Entacapone is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Entacapone.Approved
IndalpineThe risk or severity of adverse effects can be increased when Entacapone is combined with Indalpine.Investigational, Withdrawn
IproclozideThe risk or severity of adverse effects can be increased when Entacapone is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Entacapone is combined with Iproniazid.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Entacapone is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Entacapone.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Entacapone.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Entacapone.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Entacapone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Entacapone is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Entacapone is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Entacapone.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Entacapone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Entacapone is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Entacapone is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Entacapone.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Entacapone is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Entacapone.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Entacapone.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Entacapone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Entacapone.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Entacapone.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Entacapone.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Entacapone.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Entacapone.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Entacapone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Entacapone is combined with Maprotiline.Approved
MebanazineThe risk or severity of adverse effects can be increased when Entacapone is combined with Mebanazine.Withdrawn
MeclizineThe risk or severity of adverse effects can be increased when Entacapone is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Entacapone.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Entacapone.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Entacapone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Entacapone.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Entacapone.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Entacapone.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Entacapone is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Entacapone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Entacapone.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Entacapone.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Entacapone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Entacapone.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Entacapone.Approved
MethotrimeprazineEntacapone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Entacapone.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Entacapone is combined with Methsuximide.Approved
MethyldopaThe metabolism of Methyldopa can be decreased when combined with Entacapone.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Entacapone is combined with Methylene blue.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Entacapone.Approved
MetyrosineEntacapone may increase the sedative activities of Metyrosine.Approved
MicafunginThe metabolism of Micafungin can be decreased when combined with Entacapone.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Entacapone.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Entacapone is combined with Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Entacapone is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved, Investigational
MirtazapineEntacapone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Entacapone is combined with Moclobemide.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Entacapone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Entacapone.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Entacapone.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Entacapone is combined with Nefazodone.Approved, Withdrawn
NialamideThe risk or severity of adverse effects can be increased when Entacapone is combined with Nialamide.Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Entacapone.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Entacapone.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Entacapone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Entacapone is combined with Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Entacapone is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Entacapone.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Entacapone is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Entacapone.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Entacapone.Approved, Illicit
OrphenadrineEntacapone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Entacapone.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Entacapone.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Entacapone is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Entacapone.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Entacapone.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Entacapone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Entacapone.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Entacapone.Approved
ParaldehydeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineThe risk or severity of adverse effects can be increased when Entacapone is combined with Pargyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Entacapone is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Entacapone.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Entacapone.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved
PerazineThe risk or severity of adverse effects can be increased when Entacapone is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Entacapone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Entacapone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Entacapone.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Entacapone is combined with Phenelzine.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Entacapone is combined with Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Entacapone.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Entacapone.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Entacapone is combined with Phenoxypropazine.Withdrawn
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Entacapone.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Entacapone.Approved
PipamperoneThe therapeutic efficacy of Pipamperone can be decreased when used in combination with Entacapone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Entacapone is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Entacapone is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Entacapone is combined with Pirlindole.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Entacapone is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Entacapone is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Entacapone is combined with Pomalidomide.Approved
PramipexoleEntacapone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Entacapone.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Entacapone.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Entacapone.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Entacapone is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Entacapone.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Entacapone is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Entacapone.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Entacapone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Entacapone.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Entacapone is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Entacapone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Entacapone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Entacapone.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Entacapone.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Entacapone.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Entacapone.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Entacapone.Approved
RacloprideThe risk or severity of adverse effects can be increased when Entacapone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Entacapone is combined with Ramelteon.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Entacapone is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Entacapone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Entacapone.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Entacapone.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Entacapone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Entacapone is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Entacapone.Vet Approved
RopiniroleEntacapone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Entacapone.Approved
RotigotineEntacapone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Entacapone.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Entacapone.Experimental
SafrazineThe risk or severity of adverse effects can be increased when Entacapone is combined with Safrazine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Entacapone is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Entacapone is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Entacapone.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Entacapone is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Entacapone.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Entacapone is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Entacapone.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Entacapone is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Entacapone.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Entacapone.Approved
SuvorexantEntacapone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Entacapone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Entacapone is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Entacapone.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Entacapone is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Entacapone.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Entacapone.Investigational
ThalidomideEntacapone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Entacapone.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Entacapone.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Entacapone.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Entacapone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Entacapone is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Entacapone is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Entacapone.Vet Approved
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Entacapone.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Entacapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Entacapone is combined with Toloxatone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Entacapone.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Entacapone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Entacapone is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Entacapone is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Entacapone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Entacapone.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Entacapone.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Entacapone.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Entacapone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Entacapone.Approved
Uc1010The risk or severity of adverse effects can be increased when Entacapone is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Entacapone.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Entacapone is combined with Venlafaxine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Entacapone is combined with Vigabatrin.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Entacapone.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Entacapone.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Entacapone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Entacapone is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Entacapone is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Entacapone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Entacapone.Vet Approved
ZolpidemEntacapone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Entacapone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Entacapone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Entacapone.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Entacapone.Approved, Investigational
Food Interactions
  • Take without regard to meals.
References
Synthesis Reference

Pandurang Deshpande, Parven Luthra, Anand Pandey, Dharmesh Dhameliya, “Process for the preparation of (E)-2-cyano-3-(3, 4-dihydroxy-5-nitrophenyl)-N, N-diethyl-2-propenamide (entacapone).” U.S. Patent US20060258877, issued November 16, 2006.

US20060258877
General References
  1. Najib J: Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin Ther. 2001 Jun;23(6):802-32; discussion 771. [PubMed:11440283 ]
  2. Chong BS, Mersfelder TL: Entacapone. Ann Pharmacother. 2000 Sep;34(9):1056-65. [PubMed:10981253 ]
  3. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M: Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002 Apr;105(4):245-55. [PubMed:11939936 ]
  4. Brooks DJ, Sagar H: Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003 Aug;74(8):1071-9. [PubMed:12876237 ]
  5. Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Jarvinen T, Mannisto PT: Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther. 2003 Feb;304(2):498-506. [PubMed:12538800 ]
  6. Kaakkola S: Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs. 2000 Jun;59(6):1233-50. [PubMed:10882160 ]
External Links
ATC CodesN04BX02
AHFS Codes
  • 28:92.00
PDB EntriesNot Available
FDA labelDownload (52.6 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9185
Blood Brain Barrier-0.9104
Caco-2 permeable-0.5817
P-glycoprotein substrateSubstrate0.64
P-glycoprotein inhibitor INon-inhibitor0.7342
P-glycoprotein inhibitor IINon-inhibitor0.8442
Renal organic cation transporterNon-inhibitor0.9311
CYP450 2C9 substrateNon-substrate0.8406
CYP450 2D6 substrateNon-substrate0.8932
CYP450 3A4 substrateNon-substrate0.5057
CYP450 1A2 substrateNon-inhibitor0.7003
CYP450 2C9 inhibitorNon-inhibitor0.581
CYP450 2D6 inhibitorNon-inhibitor0.8548
CYP450 2C19 inhibitorNon-inhibitor0.6098
CYP450 3A4 inhibitorNon-inhibitor0.5133
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7901
Ames testAMES toxic0.5803
CarcinogenicityNon-carcinogens0.561
BiodegradationNot ready biodegradable0.9457
Rat acute toxicity2.6750 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8608
hERG inhibition (predictor II)Non-inhibitor0.8332
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Orion corp
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedOral
TabletOral200 mg
Tablet, film coatedOral200 mg
Tablet, film coatedOral200 mg/1
TabletOral
Prices
Unit descriptionCostUnit
Comtan 200 mg tablet2.96USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1334967 No1995-03-282012-03-28Canada
CA2342634 No2008-01-292019-09-13Canada
US5135950 No1993-10-312010-10-31Us
US6500867 No2000-06-292020-06-29Us
US6599530 No1998-09-142018-09-14Us
US6797732 No2000-06-292020-06-29Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0797 mg/mLALOGPS
logP2.5ALOGPS
logP1.63ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)5.68ChemAxon
pKa (Strongest Basic)-0.036ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area130.38 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity80.51 m3·mol-1ChemAxon
Polarizability29.48 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as hydroxycinnamic acids and derivatives. These are compounds containing an cinnamic acid (or a derivative thereof) where the benzene ring is hydroxylated.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassCinnamic acids and derivatives
Sub ClassHydroxycinnamic acids and derivatives
Direct ParentHydroxycinnamic acids and derivatives
Alternative Parents
Substituents
  • Hydroxycinnamic acid or derivatives
  • Nitrophenol derivative
  • Phenylpropene
  • Nitrobenzene
  • 1,2-diphenol
  • Phenol
  • Benzenoid
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Organic nitro compound
  • Tertiary amine
  • Organic nitrite
  • C-nitro compound
  • Carboxamide group
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Nitrile
  • Carbonitrile
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic zwitterion
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
O-methyltransferase activity
Specific Function:
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOPA, alpha-methyl DOPA and isoproterenol.
Gene Name:
COMT
Uniprot ID:
P21964
Molecular Weight:
30036.77 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Najib J: Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin Ther. 2001 Jun;23(6):802-32; discussion 771. [PubMed:11440283 ]
  3. Chong BS, Mersfelder TL: Entacapone. Ann Pharmacother. 2000 Sep;34(9):1056-65. [PubMed:10981253 ]
  4. Holm KJ, Spencer CM: Entacapone. A review of its use in Parkinson's disease. Drugs. 1999 Jul;58(1):159-77. [PubMed:10439935 ]
  5. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M: Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002 Apr;105(4):245-55. [PubMed:11939936 ]
  6. Brooks DJ, Sagar H: Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003 Aug;74(8):1071-9. [PubMed:12876237 ]
  7. Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Jarvinen T, Mannisto PT: Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther. 2003 Feb;304(2):498-506. [PubMed:12538800 ]
  8. Tai CH, Wu RM: Catechol-O-methyltransferase and Parkinson's disease. Acta Med Okayama. 2002 Feb;56(1):1-6. [PubMed:11873938 ]
  9. Kaakkola S: Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs. 2000 Jun;59(6):1233-50. [PubMed:10882160 ]
  10. Ruottinen HM, Rinne UK: COMT inhibition in the treatment of Parkinson's disease. J Neurol. 1998 Nov;245(11 Suppl 3):P25-34. [PubMed:9808337 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
O-methyltransferase activity
Specific Function:
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOPA, alpha-methyl DOPA and isoproterenol.
Gene Name:
COMT
Uniprot ID:
P21964
Molecular Weight:
30036.77 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Lautala P, Ethell BT, Taskinen J, Burchell B: The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos. 2000 Nov;28(11):1385-9. [PubMed:11038168 ]
  2. Kurkela M, Garcia-Horsman JA, Luukkanen L, Morsky S, Taskinen J, Baumann M, Kostiainen R, Hirvonen J, Finel M: Expression and characterization of recombinant human UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other UGTs and was purified as an active dimeric enzyme. J Biol Chem. 2003 Feb 7;278(6):3536-44. Epub 2002 Nov 14. [PubMed:12435745 ]
  3. Luukkanen L, Taskinen J, Kurkela M, Kostiainen R, Hirvonen J, Finel M: Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos. 2005 Jul;33(7):1017-26. Epub 2005 Mar 31. [PubMed:15802387 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 05, 2016 02:42